Skip to main content
REVB
NASDAQ Life Sciences

Revelation Biosciences Seeks Shareholder Approval for Another Reverse Stock Split Amidst Ongoing Nasdaq Compliance Challenges

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
8
Price
$1.13
Mkt Cap
$4.204M
52W Low
$0.99
52W High
$40.08
Market data snapshot near publication time

summarizeSummary

Revelation Biosciences proposes a reverse stock split with a wide ratio range (1-for-2 to 1-for-250) to address ongoing Nasdaq minimum bid price compliance issues, following multiple similar actions in the past year.


check_boxKey Events

  • Shareholder Vote on Reverse Stock Split

    The company is seeking shareholder authorization for its board of directors to effect a reverse stock split at a ratio between 1-for-2 and 1-for-250 within one year.

  • Addressing Nasdaq Compliance

    The primary reason for the proposed reverse stock split is to increase the per share price of common stock to regain or maintain compliance with Nasdaq's minimum bid price requirement.

  • History of Multiple Reverse Splits

    This proposal follows three previous reverse stock splits in the past year: 1-for-16 in January 2025, 1-for-3 in July 2025, and 1-for-4 in January 2026, highlighting persistent challenges with share price.

  • Context of Going Concern Warning

    This action is critical in the context of the company's 'going concern' warning disclosed in its February 2026 10-K filing, as maintaining Nasdaq listing is crucial for future financing opportunities.


auto_awesomeAnalysis

Revelation Biosciences is seeking shareholder approval for a highly dilutive reverse stock split, with a potential ratio of up to 1-for-250. This proposal is a critical measure aimed at maintaining the company's Nasdaq listing, a recurring issue as evidenced by three previous reverse splits in the past year (January 2025, July 2025, and January 2026). The need for repeated reverse splits, coupled with the company's previously disclosed 'going concern' warning from its February 2026 10-K filing, signals severe financial distress and a persistent struggle to meet listing requirements and secure long-term viability. While necessary to avoid delisting, such actions often carry a negative market perception and may not lead to a sustained increase in share price or improved liquidity.

At the time of this filing, REVB was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $0.99 to $40.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed REVB - Latest Insights

REVB
May 07, 2026, 4:23 PM EDT
Filing Type: 8-K
Importance Score:
8
REVB
May 07, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
9
REVB
Apr 30, 2026, 4:31 PM EDT
Filing Type: PRE 14A
Importance Score:
8
REVB
Mar 30, 2026, 9:00 AM EDT
Source: Access Newswire
Importance Score:
8
REVB
Mar 19, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
7
REVB
Feb 26, 2026, 4:25 PM EST
Filing Type: 8-K
Importance Score:
8
REVB
Feb 26, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
9
REVB
Feb 17, 2026, 12:35 PM EST
Filing Type: DEF 14A
Importance Score:
8
REVB
Feb 11, 2026, 5:30 PM EST
Filing Type: 424B3
Importance Score:
9
REVB
Feb 06, 2026, 4:32 PM EST
Filing Type: PRE 14A
Importance Score:
8